Volitionrx Limited (VNRX) Stock Forecast & Price Target

VolitionRX is expected to experience catalysts such as the impact of the April 28 reverse split, management's plan to regain NYSE American compliance, and the potential for further clinical publications, partnerships, and regulatory progress. Although there are significant risk factors to consider, with a 12-month price target based on a discounted cash flow model and a potential market value of $190M, the stock presents an attractive opportunity for investors.

VolitionRX is facing major challenges, including the potential for significant dilution and reduced trading liquidity following the announcement of a reverse split, as well as concerns about the company's ability to secure additional licensing deals and raise necessary capital. Additionally, while VolitionRX's Nu.Q platform has shown some promising results in detecting various diseases, including early-stage cancer, there are still concerns about its reliability and potential competition from other liquid biopsy methods. These factors, combined with the recent publication of a clinical study supporting the use of Nu.Q biomarkers in trauma patients with a high risk of developing VTE, have led to a negative outlook on the stock.